Amgen Inc. (AMGN): Price and Financial Metrics


Amgen Inc. (AMGN)

Today's Latest Price: $246.33 USD

2.51 (1.03%)

Updated Sep 28 1:26pm

Add AMGN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

AMGN Stock Summary

  • AMGN has a higher market value than 98.83% of US stocks; more precisely, its current market capitalization is $142,803,856,220.
  • Amgen Inc's stock had its IPO on January 1, 1986, making it an older stock than 92.87% of US equities in our set.
  • In terms of volatility of its share price, AMGN is more volatile than only 2.23% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Amgen Inc, a group of peers worth examining would be AZN, LLY, TXN, BMY, and SNY.
  • AMGN's SEC filings can be seen here. And to visit Amgen Inc's official web site, go to www.amgen.com.
AMGN Daily Price Range
AMGN 52-Week Price Range

AMGN Stock Price Chart Technical Analysis Charts


AMGN Price/Volume Stats

Current price $246.33 52-week high $264.97
Prev. close $243.82 52-week low $177.05
Day low $244.77 Volume 683,118
Day high $249.04 Avg. volume 2,881,532
50-day MA $246.12 Dividend yield 2.62%
200-day MA $232.02 Market Cap 144.27B

Amgen Inc. (AMGN) Company Bio


Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company was founded in 1980 and is based in Thousand Oaks, California.

AMGN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$246.33$215.09 -12%

We started the process of determining a valid price forecast for Amgen Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Amgen Inc ranked in the 41th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Amgen Inc ended up being:

  • The company has produced more trailing twelve month cash flow than 95% of its sector Healthcare.
  • Amgen Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than just 21.38% of tickers in our DCF set.
  • AMGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than just 21.38% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-14%
1%-13%
2%-12%
3%-11%
4%-10%
5%-9%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as AMGN, try DGX, STE, FONR, PRGO, and PAHC.


AMGN Latest News Stream


Event/Time News Detail
Loading, please wait...

AMGN Latest Social Stream


Loading social stream, please wait...

View Full AMGN Social Stream

Latest AMGN News From Around the Web

Below are the latest news stories about Amgen Inc that investors may wish to consider to help them evaluate AMGN as an investment opportunity.

Dow's 129-point drop led by losses for Boeing, Walt Disney shares

DOW UPDATE Shares of Boeing and Walt Disney are posting losses Thursday morning, sending the Dow Jones Industrial Average into negative territory. Shares of Boeing (BA) and Walt Disney (DIS) are contributing to the index's intraday decline, as the Dow (DJIA) was most recently trading 129 points (0.

Yahoo | September 24, 2020

Sanofi Reports Positive Lung Cancer Data, And Other News: The Good, Bad And Ugly Of Biopharma

Sanofi reports positive data for pivotal lung cancer trial Sanofi (SNY) announced positive pivotal trial data for the Libtayo as a first line treatment for locally advanced or metastatic non-small cell lung cancer. The study involved comparing Libtayo monotherapy to platinum-doublet chemotherapy in patients whose tumor cells expressed PD-L1. The...

Avisol Capital Partners on Seeking Alpha | September 23, 2020

Amgen Inc. (AMGN) Presents At ESMO Sotorasib 2020- Slideshow

The following slide deck was published by Amgen Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 23, 2020

Dow's 162-point jump led by gains for Nike, Microsoft shares

DOW UPDATE Shares of Nike and Microsoft are seeing positive growth Tuesday afternoon, propelling the Dow Jones Industrial Average into positive territory. Shares of Nike (NKE) and Microsoft (MSFT) have contributed to the blue-chip gauge's intraday rally, as the Dow (DJIA) was most recently trading 162 points higher (0.

Yahoo | September 22, 2020

Dow's nearly 100-point climb led by gains for shares of Nike, Microsoft

The Dow Jones Industrial Average is climbing Tuesday afternoon with shares of Nike and Microsoft leading the way for the index. The Dow (DJIA) was most recently trading 93 points (0.3%) higher, as shares of Nike (NKE) and Microsoft (MSFT) have contributed to the index's intraday rally. Nike's shares are up $3.32, or 2.9%, while those of Microsoft are up $3.67, or 1.8%, combining for an approximately 46-point bump for the Dow.

Yahoo | September 22, 2020

Read More 'AMGN' Stories Here

AMGN Price Returns

1-mo -2.68%
3-mo 5.14%
6-mo 26.21%
1-year 29.84%
3-year 44.01%
5-year 104.46%
YTD 4.30%
2019 27.60%
2018 15.23%
2017 22.27%
2016 -7.56%
2015 3.96%

AMGN Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full AMGN Dividend History

Continue Researching AMGN

Want to see what other sources are saying about Amgen Inc's financials and stock price? Try the links below:

Amgen Inc (AMGN) Stock Price | Nasdaq
Amgen Inc (AMGN) Stock Quote, History and News - Yahoo Finance
Amgen Inc (AMGN) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0746 seconds.